News • Entering the oncology growth market
Hologic to acquire molecular diagnostics company Biotheranostics
Hologic, Inc. has announced that it will acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments.